Postmarket Requirements Will Be "Studies" Unless "Trials" Are Needed - FDA
Executive Summary
FDA's 1draft guidance on how it will implement the authority under the FDA Amendments Act to require postmarketing research activities by sponsors defines a difference between "studies" and "clinical trials," although apparently somewhat grudgingly
You may also be interested in...
FDA Sets One-Month Target For Post-Marketing Requirement Discussions In Final Guidance
Industry wanted FDA to impose a detailed set of internal requirements on itself before imposing PMRs, but in final guidance on the subject the agency does not do so.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.